Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: Results of a prospective study

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 8, 2009, Pages 939-946

  Hille, Andrea ^a   Rave Frnk, Margret ^a   Christiansen, Hans ^a   Herrmann, Markus K A ^a   Kertesz, Tereza ^a   Hermann, Robert M ^a   Wolff, Hendrik A ^a   Schirmer, Markus ^a   Hess, Clemens F ^a   Ramadori, Giuliano ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Acute proctitis; Calprotectin; Chronic proctitis; Lactoferrin; Prostate cancer; Radiotherapy

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; LACTOFERRIN;

ARTICLE; CANCER RADIOTHERAPY; CHRONIC RADIATION PROCTITIS; CHRONIC TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION INJURY; SCORING SYSTEM; TREATMENT DURATION;

AGED; BIOLOGICAL MARKERS; FECES; HUMANS; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROCTITIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES;

EID: 70350634257     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520903039952     Document Type: Article

References (38)

1. Hille A, Schmidberger H, Hermann RM, Christiansen H, Saile B, Pradier O, et al. A phase III randomized, placebo controlled, double-blind study of misoprostol rectal suppositories in the prevention of acute radiation proctitis in patients with prostate cancer. Int J Radiat Oncol Biol Phys 2005;/63:/1488-93.
2. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, et al. Acute morbidity reduction using 3D-CRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1997;/43:/727-34.
3. Michalski JM, Purdy JA, Winter K, Roach M III, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000;/ 46:/391-402.
4. O'Brien PC, Franklin CI, Dear KB, Hamilton CC, Poulsen M, Joseph DJ, et al. A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis. Radiother Oncol 1997;/45:/117-23.
5. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;/37:/ 3-11.
6. Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol 1999;/53:/37-44.
7. Babb RR. Radiation proctitis: a review. Am J Gastroenterol 1996;/91:/1309-11.
8. Miller AR, Martenson JA, Nelson H, Schleck CD, Ilstrup DM, Gunderson LL, et al. The incidence and clinical consequences of treatment-related bowel injury. Int J Radiat Oncol Biol Phys 1999;/43:/817-25.
9. Pilepich MV, Krall J, George FW, Asbell SO, Plenk HD, Johnson RJ, et al. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984;/10:/1861-7.
10. Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990;/18:/23-9.
11. Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001;/59:/81-5.
12. Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol 2007;/42:/1440-4.
13. Gisbert JP, González-Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007;/30:/117-29.
14. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm Bowel Dis 2009; [Epub ahead of print].
15. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP, and clinical indices. Am J Gastroenterol 2008;/ 103:/162-9.
16. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009;/104:/ 673-8.
17. Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectalcancer? Scand J Gastroenterol 1993;/28:/1073-6.
18. Larsen A, Hovdenak N, Karlsdottir A, Wentzel-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers. Scand J Gastroenterol 2004;/39:/1113-8.
19. Larsen A, Bjørge B, Klementsen B, Helgeland L, Wentzel- Larsen T, Fagerhol MK, et al. Time patterns of changes in biomarkers, symptoms and histopathology during pelvic radiotherapy. Acta Oncol 2007;/46:/639-50.
20. Hille A, Schmidt-Giese E, Hermann RM, Herrmann MK, Rave-Fränk M, Schirmer M, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol 2008;/43:/52-8.
21. Wedlake L, McGough C, Hackett C, Thomas K, Blake P, Harrington K, et al. Can biological markers act as noninvasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa? Aliment Pharmacol Ther 2008;/ 27:/980-7.
22. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;/47:/ 13-47.
23. LENT soma scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31:1049-91.
24. International Commission on Radiation Units and Measurements. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. Washington, DC: International Commission on Radiation Units and Measurements; 1993.
25. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000;/48:/1111-7.
26. Sedgwick DM, Howard GC, Ferguson A. Pathogenesis of acute radiation injury to the rectum. A prospective study in patients. Int J Colorectal Dis 1994;/9:/23-30.
27. Gul YA, Prasannan S, Jabar FM, Shaker AR, Moissinac K. Pharmacotherapy for chronic hemorrhagic radiation proctitis. World J Surg 2002;/26:/1499-502.
28. Donner CS. Pathophysiology and therapy of chronic radiation- induced injury to the colon. Dig Dis 1998;/16:/253-61.
29. Haboubi NY, Schofield PF, Rowland PL. The light and electron microscopic features of early and late phase radiation- induced proctitis. Am J Gastroenterol 1988;/83:/1140-4.
30. Hasleton PS, Carr N, Schofield PF. Vascular changes in radiation bowel disease. Histopathology 1985;/9:/517-34.
31. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;/39:/ 1017-20.
32. Sugi, K, O. Saitoh, I. Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel: comparison with other neutrophil derived proteins. Am J Gastroenterol 1996;91:927-34.
33. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995;/80:/252-67.
34. Voganatsi A, Panyutich A, Miyasaki KT, Murthy RK. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol 2001;/70:/130-4.
35. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;/272:/9496-502.
36. Kayazawa M, Saitoh O, Kojima K, Nakagawa K, Tanaka S, Tabata K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 2002;/97:/360-9.
37. Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005;/ 51:/117-26.
38. Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, et al. Is there more than one late radiation proctitis syndrome? Radiother Oncol 1999;/51:/43-53.